Literature DB >> 21255656

Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging.

Jing Yang1, Youssef Zaim Wadghiri, Dung Minh Hoang, Wai Tsui, Yanjie Sun, Erika Chung, Yongsheng Li, Andrew Wang, Mony de Leon, Thomas Wisniewski.   

Abstract

Amyloid plaques are one of the pathological hallmarks of Alzheimer's disease (AD). The visualization of amyloid plaques in the brain is important to monitor AD progression and to evaluate the efficacy of therapeutic interventions. Our group has developed several contrast agents to detect amyloid plaques in vivo using magnetic resonance microimaging (μMRI) in AD transgenic mice, where we used intra-carotid mannitol to enhance blood-brain barrier (BBB) permeability. In the present study, we used ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles, chemically coupled with Aβ1-42 peptide to detect amyloid deposition along with mannitol for in vivo μMRI by femoral intravenous injection. A 3D gradient multi-echo sequence was used for imaging with a 100μm isotropic resolution. The amyloid plaques detected by T2*-weighted μMRI were confirmed with matched histological sections. Furthermore, two different quantitative analyses were used. The region of interest-based quantitative measurement of T2* values showed contrast-injected APP/PS1 mice had significantly reduced T2* values compared to wild-type mice. In addition, the scans were examined with voxel-based morphometry (VBM) using statistical parametric mapping (SPM) for comparison of contrast-injected AD transgenic and wild-type mice. The regional differences seen in VBM comparing USPIO-Aβ1-42 injected APP/PS1 and wild-type mice correlated with the amyloid plaque distribution histologically, contrasting with no differences between the two groups of mice without contrast agent injection in regions of the brain with amyloid deposition. Our results demonstrated that both approaches were able to identify the differences between AD transgenic mice and wild-type mice, after injected with USPIO-Aβ1-42. The feasibility of using less invasive intravenous femoral injections for amyloid plaque detection in AD transgenic mice facilitates using this method for longitudinal studies in the pathogenesis of AD.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21255656      PMCID: PMC3085913          DOI: 10.1016/j.neuroimage.2011.01.023

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  57 in total

1.  Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging.

Authors:  Niels Braakman; Jörg Matysik; Sjoerd G van Duinen; Fons Verbeek; Reinhard Schliebs; Huub J M de Groot; A Alia
Journal:  J Magn Reson Imaging       Date:  2006-09       Impact factor: 4.813

Review 2.  Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review.

Authors:  Jason S Weinstein; Csanad G Varallyay; Edit Dosa; Seymur Gahramanov; Bronwyn Hamilton; William D Rooney; Leslie L Muldoon; Edward A Neuwelt
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-16       Impact factor: 6.200

3.  Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease.

Authors:  Nadine El Tannir El Tayara; Benoît Delatour; Camille Le Cudennec; Maryvonne Guégan; Andreas Volk; Marc Dhenain
Journal:  Neurobiol Dis       Date:  2005-12-07       Impact factor: 5.996

Review 4.  Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program.

Authors:  Hamm Bernd; Eric De Kerviler; Sophie Gaillard; Bruno Bonnemain
Journal:  Invest Radiol       Date:  2009-06       Impact factor: 6.016

5.  Magnetic resonance imaging of amyloid plaques in transgenic mice.

Authors:  Youssef Zaim Wadghiri; Einar M Sigurdsson; Thomas Wisniewski; Daniel H Turnbull
Journal:  Methods Mol Biol       Date:  2005

6.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes.

Authors:  L Holcomb; M N Gordon; E McGowan; X Yu; S Benkovic; P Jantzen; K Wright; I Saad; R Mueller; D Morgan; S Sanders; C Zehr; K O'Campo; J Hardy; C M Prada; C Eckman; S Younkin; K Hsiao; K Duff
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

7.  Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging.

Authors:  Youssef Zaim Wadghiri; Einar M Sigurdsson; Marcin Sadowski; James I Elliott; Yongsheng Li; Henrieta Scholtzova; Cheuk Ying Tang; Gilbert Aguinaldo; Miguel Pappolla; Karen Duff; Thomas Wisniewski; Daniel H Turnbull
Journal:  Magn Reson Med       Date:  2003-08       Impact factor: 4.668

Review 8.  Abeta aggregation and possible implications in Alzheimer's disease pathogenesis.

Authors:  Prashant R Bharadwaj; Ashok K Dubey; Colin L Masters; Ralph N Martins; Ian G Macreadie
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

9.  Voxel-based morphometry in the R6/2 transgenic mouse reveals differences between genotypes not seen with manual 2D morphometry.

Authors:  S J Sawiak; N I Wood; G B Williams; A J Morton; T A Carpenter
Journal:  Neurobiol Dis       Date:  2008-10-01       Impact factor: 5.996

Review 10.  Recent developments in Alzheimer's disease therapeutics.

Authors:  Michael S Rafii; Paul S Aisen
Journal:  BMC Med       Date:  2009-02-19       Impact factor: 8.775

View more
  32 in total

Review 1.  Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents.

Authors:  Houshang Amiri; Kolsoum Saeidi; Parvin Borhani; Arash Manafirad; Mahdi Ghavami; Valerio Zerbi
Journal:  ACS Chem Neurosci       Date:  2013-09-26       Impact factor: 4.418

2.  Gd(3+) complexes conjugated to Pittsburgh compound B: potential MRI markers of β-amyloid plaques.

Authors:  André F Martins; Jean-François Morfin; Carlos F G C Geraldes; Eva Tóth
Journal:  J Biol Inorg Chem       Date:  2013-12-03       Impact factor: 3.358

3.  Magnetic nanoparticles and their applications in image-guided drug delivery.

Authors:  Mi Kyung Yu; Jinho Park; Sangyong Jon
Journal:  Drug Deliv Transl Res       Date:  2012-02       Impact factor: 4.617

4.  Deciphering the Biochemical Pathway and Pharmacokinetic Study of Amyloid βeta-42 with Superparamagnetic Iron Oxide Nanoparticles (SPIONs) Using Systems Biology Approach.

Authors:  Aman Chandra Kaushik; Ajay Kumar; Vivek Dhar Dwivedi; Shiv Bharadwaj; Sanjay Kumar; Kritika Bharti; Pavan Kumar; Ravi Kumar Chaudhary; Sarad Kumar Mishra
Journal:  Mol Neurobiol       Date:  2017-05-06       Impact factor: 5.590

5.  Detection of β-Amyloid by Sialic Acid Coated Bovine Serum Albumin Magnetic Nanoparticles in a Mouse Model of Alzheimer's Disease.

Authors:  Seyedmehdi Hossaini Nasr; Hovig Kouyoumdjian; Christiane Mallett; Sherif Ramadan; David C Zhu; Erik M Shapiro; Xuefei Huang
Journal:  Small       Date:  2017-11-14       Impact factor: 13.281

Review 6.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 7.  Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective.

Authors:  Javed Ahmad; Sohail Akhter; Md Rizwanullah; Mohammad Ahmed Khan; Lucie Pigeon; Richard T Addo; Nigel H Greig; Patrick Midoux; Chantal Pichon; Mohammad Amjad Kamal
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

8.  SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AβPP/PS-1 transgenic mouse brain.

Authors:  Laurel O Sillerud; Nathan O Solberg; Ryan Chamberlain; Robert A Orlando; John E Heidrich; David C Brown; Christina I Brady; Thomas A Vander Jagt; Michael Garwood; David L Vander Jagt
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

9.  Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates.

Authors:  André F Martins; Alexandre C Oliveira; Jean-François Morfin; Douglas V Laurents; Éva Tóth; Carlos F G C Geraldes
Journal:  J Biol Inorg Chem       Date:  2015-11-27       Impact factor: 3.358

10.  Cerebral vascular leak in a mouse model of amyloid neuropathology.

Authors:  Eric A Tanifum; Zbigniew A Starosolski; Stephanie W Fowler; Joanna L Jankowsky; Ananth V Annapragada
Journal:  J Cereb Blood Flow Metab       Date:  2014-07-23       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.